The administration of gemfibrozil at higher dosage increased the expression of CPT1C inhibited by Aβ25-35, which tallied with the idea proposed by several experts that alteration of PPARα signaling may lead to activation of APP metabolism that contributed to AD pathogenesis [30]. This evidence concerns the gene APP and Alzheimer disease.